A study revealed that Jun13296, a novel PLpro inhibitor, demonstrates potent antiviral and anti-inflammatory effects in vivo, offering hope for future COVID-19 therapies beyond Paxlovid. Study: Design ...
University of Arizona has identified non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results